Gilead Sciences Stock Surges 9% on Strong Q2 Earnings

Gilead Sciences, Inc. (GILD.US) saw its stock price surge by nearly 9% on Friday, closing at $120.07. The company's second-quarter financial results for 2025 outperformed market expectations, with revenue increasing by 2% to $7.08 billion, surpassing the anticipated $6.98 billion. The adjusted earnings per share stood at $2.01, exceeding the market's forecast of $1.96. This strong performance was driven by the growth of key products such as Biktarvy, Descovy, Trodelvy, and Livdelzi, as highlighted by CEO Daniel O'Day.

For the full year, Gilead Sciences has revised its guidance, projecting product sales to be between $28.3 billion and $28.7 billion, an increase of $1 billion from its previous estimate. The company also expects earnings per share to range from $5.85 to $6.15, up from the previous range of $5.65 to $6.05. On an adjusted basis, the company anticipates earnings per share to be between $7.95 and $8.25, revised from the previous range of $7.70 to $8.10. These upward revisions reflect the company's confidence in its continued growth and financial performance.

Gilead Sciences' ability to exceed market expectations and maintain strong financial health is a testament to its strategic initiatives and operational efficiency. The company's robust financial performance and upward revision of its annual guidance have been well-received by investors, contributing to the stock's impressive gains. This positive outlook indicates that Gilead Sciences is well-positioned to continue its growth trajectory in the coming quarters.